AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel.
Media Center
09.09.2024
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
29.12.2020
The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
